This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 Mar 31;352(13):1387; author reply 1387.

doi: 10.1056/NEJM200503313521325.

Rivastigmine for dementia associated with Parkinson's disease

Caroline N Harada, Joseph W Shega, Greg A Sachs

PMID: 15800242
DOI: 10.1056/NEJM200503313521325

Comment

Rivastigmine for dementia associated with Parkinson's disease

Caroline N Harada et al. N Engl J Med. 2005.

. 2005 Mar 31;352(13):1387; author reply 1387.

doi: 10.1056/NEJM200503313521325.

Authors

Caroline N Harada, Joseph W Shega, Greg A Sachs

PMID: 15800242
DOI: 10.1056/NEJM200503313521325

No abstract available

PubMed Disclaimer

Comment on

Rivastigmine for dementia associated with Parkinson's disease.
Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R. Emre M, et al. N Engl J Med. 2004 Dec 9;351(24):2509-18. doi: 10.1056/NEJMoa041470. N Engl J Med. 2004. PMID: 15590953 Clinical Trial.

Similar articles

Rivastigmine for dementia associated with Parkinson's disease.
Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R. Emre M, et al. N Engl J Med. 2004 Dec 9;351(24):2509-18. doi: 10.1056/NEJMoa041470. N Engl J Med. 2004. PMID: 15590953 Clinical Trial.
[Rivastigmine against dementia in Parkinson disease?].
Landmark K, Reikvam A. Landmark K, et al. Tidsskr Nor Laegeforen. 2007 Nov 15;127(22):2973; author reply 2973-4. Tidsskr Nor Laegeforen. 2007. PMID: 18026256 Norwegian. No abstract available.
Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
Wesnes K. Wesnes K. Drugs Today (Barc). 2007 Jun;43(6):349-59. doi: 10.1358/dot.2007.43.6.1107987. Drugs Today (Barc). 2007. PMID: 17612707 Review.
Rivastigmine for dementia associated with Parkinson's disease.
Morgan J, Sethi KD. Morgan J, et al. Curr Neurol Neurosci Rep. 2005 Jul;5(4):263-5. doi: 10.1007/s11910-005-0070-8. Curr Neurol Neurosci Rep. 2005. PMID: 15987609 Clinical Trial. No abstract available.
Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Darreh-Shori T, Jelic V. Darreh-Shori T, et al. Expert Opin Drug Saf. 2010 Jan;9(1):167-76. doi: 10.1517/14740330903439717. Expert Opin Drug Saf. 2010. PMID: 20021294 Review.

See all similar articles

Cited by

Modulation of the rat hippocampal-cortex network and episodic-like memory performance following entorhinal cortex stimulation.
Jiang Y, Liu DF, Zhang X, Liu HG, Zhang C, Zhang JG. Jiang Y, et al. CNS Neurosci Ther. 2022 Mar;28(3):448-457. doi: 10.1111/cns.13795. Epub 2021 Dec 28. CNS Neurosci Ther. 2022. PMID: 34964261 Free PMC article.
Rivastigmine for the treatment of dementia associated with Parkinson's disease.
Reingold JL, Morgan JC, Sethi KD. Reingold JL, et al. Neuropsychiatr Dis Treat. 2007 Dec;3(6):775-83. doi: 10.2147/ndt.s1134. Neuropsychiatr Dis Treat. 2007. PMID: 19300613 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information